메뉴 건너뛰기




Volumn 12, Issue 3, 2009, Pages 238-245

Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer

Author keywords

Breast cancer; Capecitabine; Cost analyses; Medicare and Medicaid; Oral chemotherapy

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; ZOLEDRONIC ACID;

EID: 75149182921     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903269673     Document Type: Article
Times cited : (5)

References (25)
  • 1
    • 0003964363 scopus 로고    scopus 로고
    • American Cancer Society. Available at
    • American Cancer Society. Cancer Facts & Figures. 2007. Available at: www.cancer.org.
    • (2007) Cancer Facts & Figures
  • 2
    • 0032824734 scopus 로고    scopus 로고
    • Current management of metastatic breast cancer
    • Perez EA. Current management of metastatic breast cancer. Semin Oncol 1999;26:1-10.
    • (1999) Semin Oncol , vol.26 , pp. 1-10
    • Perez, E.A.1
  • 3
    • 14844303761 scopus 로고    scopus 로고
    • Capecitabine: A review
    • Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005;27:23-44.
    • (2005) Clin Ther , vol.27 , pp. 23-44
    • Walko, C.M.1    Lindley, C.2
  • 4
    • 18444417397 scopus 로고    scopus 로고
    • Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines
    • Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86:1367-1372.
    • (2002) Br J Cancer , vol.86 , pp. 1367-1372
    • Talbot, D.C.1    Moiseyenko, V.2    Van Belle, S.3
  • 5
    • 1842627763 scopus 로고    scopus 로고
    • Oral capecitabine in anthracycline-and taxane-pretreated advanced/metastatic breast cancer
    • Wist EA, Sommer HH, Ostenstad B, et al. Oral capecitabine in anthracycline-and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 2004;43:186-189.
    • (2004) Acta Oncol , vol.43 , pp. 186-189
    • Wist, E.A.1    Sommer, H.H.2    Ostenstad, B.3
  • 7
    • 0041508753 scopus 로고    scopus 로고
    • Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy
    • Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14:1227-1233.
    • (2003) Ann Oncol , vol.14 , pp. 1227-1233
    • Reichardt, P.1    Von Minckwitz, G.2    Thuss-Patience, P.C.3
  • 8
    • 0034778024 scopus 로고    scopus 로고
    • Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer
    • O'Shaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12:1247-1254.
    • (2001) Ann Oncol , vol.12 , pp. 1247-1254
    • O'Shaughnessy, J.A.1    Blum, J.2    Moiseyenko, V.3
  • 9
    • 41849091764 scopus 로고    scopus 로고
    • A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment
    • ASCO Annual Meeting Proceedings, (16S), Part I of II
    • Stockler M, Sourijina T, Grimision P, et al. A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(June Suppl): (16S), Part I of II, 1031.
    • (2007) J Clin Oncol , vol.25 , Issue.JUNE SUPPL. , pp. 1031
    • Stockler, M.1    Sourijina, T.2    Grimision, P.3
  • 10
    • 33644960128 scopus 로고    scopus 로고
    • Capecitabine monotherapy for elderly patients with metastatic breast cancer
    • Minea L, Stanculeanu DL, Cringeanu A, et al. Capecitabine monotherapy for elderly patients with metastatic breast cancer. J Clin Oncol 2004;22:76s.
    • (2004) J Clin Oncol , vol.22
    • Minea, L.1    Stanculeanu, D.L.2    Cringeanu, A.3
  • 11
    • 20244368234 scopus 로고    scopus 로고
    • Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women
    • Bajetta E, Procopio G, Gelio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23:2155-2166.
    • (2005) J Clin Oncol , vol.23 , pp. 2155-2166
    • Bajetta, E.1    Procopio, G.2    Gelio, L.3
  • 13
    • 0012856124 scopus 로고    scopus 로고
    • Phase II study of vinorelbine (Navelline) and capecitabine (C) combination (Navcap) as first line treatment of metastatic breast cancer (MBC)
    • Kattan J, Ghosn M, Farhat F, et al. Phase II study of vinorelbine (Navelline) and capecitabine (C) combination (Navcap) as first line treatment of metastatic breast cancer (MBC). Ann Oncol 2002;13(Suppl 5):56.
    • (2002) Ann Oncol , vol.13 , Issue.SUPPL. 5 , pp. 56
    • Kattan, J.1    Ghosn, M.2    Farhat, F.3
  • 14
    • 0003043509 scopus 로고    scopus 로고
    • Population based cost-effectiveness analysis of combination capecitabine and docstaxel (DC) versus single agent docetaxel (D) in the treatment of metastatic breast cancer (MBC) following an anthracycline regimen
    • Malfair TS, Barnett J, Chia S. Population based cost-effectiveness analysis of combination capecitabine and docstaxel (DC) versus single agent docetaxel (D) in the treatment of metastatic breast cancer (MBC) following an anthracycline regimen. Eur J Cancer 2002;38(Suppl 3):S67.
    • (2002) Eur J Cancer , vol.38 , Issue.SUPPL. 3
    • Malfair, T.S.1    Barnett, J.2    Chia, S.3
  • 15
    • 20444389366 scopus 로고    scopus 로고
    • Capecitabine plus docetaxel combination therapy
    • Verma S, Maraninchi D, O'Shaughnessy J, et al. Capecitabine plus docetaxel combination therapy. Cancer 2005;103:2455-2465.
    • (2005) Cancer , vol.103 , pp. 2455-2465
    • Verma, S.1    Maraninchi, D.2    O'Shaughnessy, J.3
  • 16
    • 0037683726 scopus 로고    scopus 로고
    • Population-based pharmacoeconomic model for adopting capecitabine/ docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer
    • Verma S, Ilersich AL. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline- pretreated metastatic breast cancer. Oncologist 2003;8:232-240.
    • (2003) Oncologist , vol.8 , pp. 232-240
    • Verma, S.1    Ilersich, A.L.2
  • 17
    • 75149130914 scopus 로고    scopus 로고
    • Economic evaluation of capecitabine-docetaxel combination study
    • Hornberger JC, Jamieson C, O'Shaughnessy J. Economic evaluation of capecitabine-docetaxel combination study. Value Health 2002;5:129.
    • (2002) Value Health , vol.5 , pp. 129
    • Hornberger, J.C.1    Jamieson, C.2    O'Shaughnessy, J.3
  • 18
    • 1442321206 scopus 로고    scopus 로고
    • Clinical and economic outcomes associated with metastatic breast cancer in managed care populations: Capecitabine (Xeloda) versus comparison therapies
    • abstr 1942 ASCO Annual Meeting Proceedings
    • Baran RW, Dupere W, Susan M, et al. Clinical and economic outcomes associated with metastatic breast cancer in managed care populations: capecitabine (Xeloda) versus comparison therapies. ASCO Annual Meeting Proceedings, J Clin Oncol 2002, abstr 1942.
    • (2002) J Clin Oncol
    • Baran, R.W.1    Dupere, W.2    Susan, M.3
  • 19
    • 25544437658 scopus 로고    scopus 로고
    • Cost-effectiveness of capecitabine, continuous infusion 5-FU, gemcitabine and vinorebine in the treatment of metastatic breast cancer
    • abstr 1629 ASCO Annual Meeting Proceedings
    • Silberman G, Gupta S, Berkowitz N, et al. Cost-effectiveness of capecitabine, continuous infusion 5-FU, gemcitabine and vinorebine in the treatment of metastatic breast cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 1999, abstr 1629.
    • (1999) J Clin Oncol
    • Silberman, G.1    Gupta, S.2    Berkowitz, N.3
  • 20
    • 75749137109 scopus 로고    scopus 로고
    • Use of cancer registry data for research on patterns of breast cancer care of individuals with Medicaid Insurance
    • ASCO Annual Meeting Proceedings: (16S), Part I of II
    • Anderson RT, Camacho FT, Balkrishnan R, et al. Use of cancer registry data for research on patterns of breast cancer care of individuals with Medicaid Insurance. ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25(June Suppl): (16S), Part I of II, 6021.
    • (2007) J Clin Oncol , vol.25 , Issue.JUNE SUPPL. , pp. 6021
    • Anderson, R.T.1    Camacho, F.T.2    Balkrishnan, R.3
  • 21
    • 0030472186 scopus 로고    scopus 로고
    • Practical considerations on the use of the Charlson comorbidity with administrative data bases
    • D'Hoore W, Bouckaert A, Tilquin Ch. Practical considerations on the use of the Charlson comorbidity with administrative data bases. J. Clin Epidemiol 1996;49:1429-1433.
    • (1996) J. Clin Epidemiol , vol.49 , pp. 1429-1433
    • D'Hoore, W.1    Bouckaert, A.2    Tilquin, Ch.3
  • 23
    • 0037271111 scopus 로고    scopus 로고
    • Breast cancer management: Quality-of-life and cost considerations
    • DOI 10.2165/00019053-200321060-00003
    • Radice D, Redaelli A. Breast cancer management: quality-of-life and cost considerations. Pharmacoeconomics 2003;21:383-396. (Pubitemid 36461402)
    • (2003) PharmacoEconomics , vol.21 , Issue.6 , pp. 383-396
    • Radice, D.1    Redaelli, A.2
  • 24
    • 43149114465 scopus 로고    scopus 로고
    • Assessing the economic burden of breast cancer in a US managed care population
    • Barron JJ, Quimbo R, Nikam PT, et al. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat 2008;109:367-377.
    • (2008) Breast Cancer Res Treat , vol.109 , pp. 367-377
    • Barron, J.J.1    Quimbo, R.2    Nikam, P.T.3
  • 25
    • 4444356391 scopus 로고    scopus 로고
    • The vital role of education and information in patients receiving capecitabine (Xeloda)
    • Chau I, Legge S, Fumoleau P. The vital role of education and information in patients receiving capecitabine (Xeloda). Eur J Oncol Nurs 2004;8(Suppl 1):S41-53.
    • (2004) Eur J Oncol Nurs , vol.8 , Issue.SUPPL. 1
    • Chau, I.1    Legge, S.2    Fumoleau, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.